Cardiac Science invites Spacelabs to merge

Article

November was a banner month for medical market consolidation, with Philips/ADAC, Cerner/ADAC, Philips/Agilent, Kodak/Lumisys, and Kodak/R2 among the more prominent deals. Now Cardiac Science has offered to buy Spacelabs Medical for about $143

November was a banner month for medical market consolidation, with Philips/ADAC, Cerner/ADAC, Philips/Agilent, Kodak/Lumisys, and Kodak/R2 among the more prominent deals. Now Cardiac Science has offered to buy Spacelabs Medical for about $143 million, paying $15 per share for all outstanding common stock, a 45% premium over the Nov. 13 per-share price.

Spacelabs rebuffed an offer made by Cardiac Science in mid-November, prompting Cardiac Science to publish its offer openly. The company has already acquired 320,200 shares of Spacelabs and has nominated a full slate of alternate candidates for the Spacelabs board of directors.

Cardiac Science plans to integrate its automatic defibrillation technology into Spacelabs' installed base of approximately 65,000 hospital patient monitors, according to Raymond Cohen, the company's president and CEO. Cardiac wants to accelerate the adoption of its core technology by other players in the cardiac patient monitoring market, including Philips (through its acquisition of Agilent Healthcare Solutions Group), GE Medical, Siemens, and Datex Ohmeda, by exploiting Spacelabs' customer base and its cardiac telemetry and telemedicine monitoring products.


© 2000 Miller Freeman Inc.
12/13/00, Issue # 118, page 3.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.